

(I)


wherein

W is oxygen or sulphur;

R is  $-\text{OR}^4$ ,  $-\text{SR}^4$ ,  $-\text{SOR}^4$ ,  $-\text{SO}_2\text{R}^4$ , or  $\text{R}^4$ , wherein  $\text{R}^4$  is propynyl substituted with phenoxy, wherein the phenoxy is optionally substituted with one or more halogen(s),  $-\text{OH}$ ,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $\text{C}_{1-4}$ -alkyl,  $\text{C}_{1-4}$ -alkylthio,  $\text{C}_{1-4}$ -alkoxy,  $-\text{SCF}_3$ ,  $-\text{OCF}_3$ ,  $-\text{CF}_3$ ,  $-\text{CONH}_2$  or  $-\text{CSNH}_2$ ;

r is 0, 1 or 2; and

G is an azabicyclic ring system which is:



(G)

wherein the thiadiazole ring is attached at any appropriate position;

$\text{R}^1$  and  $\text{R}^2$  independently are hydrogen,  $-\text{OH}$ ,  $=\text{O}$ ,  $\text{C}_{1-15}$ -alkyl,  $\text{C}_{2-15}$ -alkenyl,  $\text{C}_{2-15}$ -alkynyl,  $\text{C}_{1-10}$ -alkoxy, and  $\text{C}_{1-5}$ -alkyl substituted with one or more halogen(s),  $-\text{OH}$ ,  $-\text{COR}^8$ ,  $-\text{CH}_2\text{OH}$ ,  $-\text{NH}_2$ , carboxy and phenyl;

$\text{R}^8$  is hydrogen, or  $\text{C}_{1-6}$ -alkyl;

..... is a single or double bond;

or a pharmaceutically acceptable salt or solvate thereof.

33. (Amended) A compound of claim 25 wherein  $\text{R}^4$  is 2-propyn-1-yl.

**Response**

Claims 31 and 32 have been cancelled without prejudice or disclaimer. Claims 25 and 33 have been amended. Following entry of this amendment, claims 25 -30 and 33-37 are pending in the present application.


Claims 25-30 and 32-37 stand rejected under 35 U.S.C. 103(a) as being obvious in view of US Patent No. 5,821,371 (*Alt et. al*). Claim 25 has been amended to incorporate the limitations of allowed claim 31. Claim 33 has been amended to properly depend on claim 25.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "Version with Markings to Show Changes Made".

Applicant submits the present amendment presents no new issues or new matter. Reconsideration of the application in view of the above amendments and remarks is respectfully requested. In view of the above, Applicant submits all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Date: June 10, 2003

Respectfully submitted,



Rosemarie R. Wilk-Orescan  
Registration Number 45,220  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5969



23650

PATENT TRADEMARK OFFICE